medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (3)

Nail Psoriasis: Therapeutical Options

Gallegos RMA, Villanueva QDG, Barba GJF

Language: Spanish
References: 50
Page: 237-244
PDF size: 149.90 Kb.


ABSTRACT

Psoriasis is a chronic, cytokine-mediated, autoinflammatory disease that to this day remains incurable. Skin, joints and nails can all be affected. Nail involvement is present in more than 50% of patients, it can have a significant impact in their quality of life and can be difficult to treat. Biological agents are by far the most effective. We present a review of treatment options for patients with nail psoriasis.


REFERENCES

  1. van de Kerkhof PCM, Nestle FO. Psoriasis. En: Bolognia JL, Jorizzo JL, Schaffer JV, editores. Dermatology. 3a ed. China: Elsevier 2012; 135-156.

  2. Rosso KR, Murussi N, Neumaier W et al. Nail psoriasis: a review of the literature. An Bras Dermatol 2014; 89(2): 312-7.

  3. Gudjonsson JE, Elder JT. Psoriasis. En: Goldsmith LA, Katz SI, Paller AS, editores. Fitzpatrick Dermatología en Medicina General. 8a ed. Madrid: Panamericana 2014; 197-232.

  4. Sánchez-Regaña M, Umbert-Millet P. Aspectos diagnósticos y terapéuticos de la psoriasis ungueal. Actas Dermosifiliogr 2008; 99(1): 34-43.

  5. Tan ES, Chong WS, Tey HL. Nail Psoriasis: A Review. Am J Clin Dermatol 2012; 13(6): 375-88.

  6. de Vries ACQ, Bogaards NA, Hooft L et al. Interventions for nail psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 1; Art. No.: CD007633. DOI: 10.1002/14651858.CD007633.pub2.

  7. Langley RG, Saurat JH, Reich K. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol 2012; 26(3): 373-81.

  8. Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016; 76(6): 675-705.

  9. Langenbruch A, Radtke MA, Krensel M et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol 2014; 171(5): 1123-8.

  10. Oram Y, Akkaya D. Treatment of Nail Psoriasis: Common Concepts and New Trends. Dermatol Res Pract 2013; 2013(5): 180496. doi: 10.1155/2013/180496.

  11. Tosti A, Piraccini BM. Biología de las uñas y trastornos ungueales. En: Goldsmith LA, Katz SI, Paller AS, editores. Fitzpatrick Dermatología en Medicina General. 8a ed. Madrid: Panamericana 2014; 1009-30.

  12. Wiznia LE, Quatrano NA, Mu EW, Rieder EA. A Clinical Review of Laser and Light Therapy for Nail Psoriasis and Onychomycosis. Dermatol Surg 2016; [Epub ahead of print]

  13. Radtke MA, Langenbruch AK, Schäfer I et al. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2011; 2: 1-6.

  14. de Jong EM, Seegers BA, Gulinck MK et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193(4): 300-3.

  15. Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010; 221: 1-5.

  16. Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid- containing nail lacquer formulation. J Dermatol Treat 1999; 10(3): 201-4.

  17. Nakamura RC, Abreu LD, Duque-Estrada B et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treat- ment: prospective, controlled and randomized pilot study. An Bras Dermatol 2012; 87(2): 203-11.

  18. Sánchez-Regaña M, Ojeda-Cuchillero R, Umbert-Millet P. Empleo de calcipotriol tópico en la psoriasis ungueal. Piel 2002; 17(3): 104-8.

  19. Tosti A, Piraccini BM, Cameli N et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139(4): 655-9.

  20. Márquez-Balbás G, Sánchez-Regaña M, Umbert-Millet P. Tacalcitol ointment for the treatment of nail psoriasis. J Dermatolog Treat 2009; 20(5): 308-10.

  21. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05 % cream: a double-blind study. Acta Derm Venereol 2007; 87(2): 167-8.

  22. Fischer C, Sanchez M, Llambi F et al. Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermosifiliogr 2012; 103(8): 725-8.

  23. Cannavo SP, Guarneri F, Vaccaro M et al. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003; 206(2): 153-6.

  24. De Simone C, Maiorino A, Tassone F et al. Tacrolimus 0.1 % ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol 2013; 27(8): 1003-6.

  25. Fritz K. Successful local treatment of nail psoriasis with 5-fluorouracil. Z Hautkr 1989; 64(12): 1083-8.

  26. Maranda EL, Nguyen AH, Lim VM et al. Laser and light therapies for the treatment of nail psoriasis. J Eur Acad Dermatol Venereol 2016; 30(8): 1278-84.

  27. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25(4): 231–3.

  28. 28.- Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. “Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)”. J Eur Acad Dermatol Venereol 2011; 25(5): 579–586.

  29. 29.- Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. “Evaluation of the efficacy of acitretin therapy for nail psoriasis”. Arch Dermatol 2009; 145(3): 269–271.

  30. Mukai MM, Poffo IF, Werner B et al. NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin. An Bras Dermatol 2012; 87(2): 256-62.

  31. Gumusel M, Ozdemir M, Mevlitoglu I, Bodur S. Evaluation of the effi- cacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25(9): 1080-4.

  32. Lee JY. Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online J 2009; 15(11): 8.

  33. Karanikolas GN, Koukli EM, Katsalira A et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011; 38(11): 2466-74.

  34. Feliciani C, Zampetti A, Forleo P et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 2004; 8(2): 122-5.

  35. Rigopoulos D, Gregoriou S, Stratigos A et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159(2): 453-6.

  36. Rich P, Griffiths CE, Reich K et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58(2): 224-31.

  37. Ortonne JP, Paul C, Berardesca E et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 2013; 168(5): 1080-7.

  38. Van den Bosch F, Manger B, Goupille P et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394-9.

  39. Armesto S, Esteve A, Coto P et al. Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients. Actas Dermosifiliogr 2011; 102(5): 365-72.

  40. Saraceno R, Pietroleonardo L, Mazzotta A et al. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther 2013; 13(4): 469-473.

  41. Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat 2013; 24(3): 162-8.

  42. Leonardi C, Langley RG, Papp K et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147(4): 429-36.

  43. Crowley JJ, Weinberg JM, Wu JJ et al. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015; 151(1): 87-94.

  44. Saricaoglu H, Oz A, Turan H. Nail psoriasis successfully treated with intralesional methotrexate: case report. Dermatology 2011; 222(1): 5-7.

  45. Aubin F, Vigan M, Puzenat E et al. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol 2005; 152(1): 99-103.

  46. Fernández-Guarino M, Harto A, Sánchez-Ronco M et al. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. J Eur Acad Dermatol Venereol 2009; 23(8): 891-5.

  47. Tawfik AA. Novel treatment of nail psoriasis using the intense pulsed light: a one-year follow-up study. Dermatol Surg 2014; 40(7): 763-8.

  48. Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, doubleblind, intrapatient left-to-right study. J Am Acad Dermatol 2012; 66(5): 807-12.

  49. Oram Y, Karincaoglu Y, Koyuncu E, Kaharaman F. Pulsed dye laser in the treatment of nail psoriasis. Dermatol Surg 2010; 36(3): 377-81.

  50. Al-Mutairi N, Noor T, Al-Haddad A. Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis. Dermatol Ther (Heidelb) 2014; 4(2): 197-205.




2020     |     www.medigraphic.com